secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001140361-26-009735
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics appoints Dr. Henry Brem to board of directors
-------------------------------------------------------------------

- Dr. Henry Brem appointed as independent director effective March 12, 2026.
- Brem is a neurosurgeon-scientist at Johns Hopkins and former Director of Neurosurgery.
- He brings expertise in translational medicine and clinical development of novel therapies.
- Will receive standard non-employee director compensation per existing program.
- No reportable transactions between Brem and the company under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126009735/0001140361-26-009735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126009735/ef20068034_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-009735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer